A Phase I, Open-Label, Dose Escalation and Extension Study to Evaluate the Safety, Tolerability and Preliminary Effects of Oral BEL-X-HG in Patients With Advanced Refractory Solid Malignancies
This is a Phase I, open-label, uncontrolled, multicenter dose escalation and extension study to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate safety / tolerability and preliminary effects of BEL-X-HG in patients with advanced refractory solid tumors. Dose escalation during the study will be made based on dose-limiting toxicity (DLT).
100 Clinical Results associated with Belx Bio-Pharmaceutical (Taiwan) Corporation
0 Patents (Medical) associated with Belx Bio-Pharmaceutical (Taiwan) Corporation
100 Deals associated with Belx Bio-Pharmaceutical (Taiwan) Corporation
100 Translational Medicine associated with Belx Bio-Pharmaceutical (Taiwan) Corporation